RFI Ingredients Takes On Minority Investment From Astanor to Fund Global Expansion

RFI Ingredients, a vertically integrated supplier of botanical extracts and specialty nutritional ingredients, announced a strategic growth partnership with global agrifood investment firm Astanor.¹

The investment is structured as a minority stake, with founder and CEO Jeff Wuagneux retaining majority ownership and continuing to lead the company alongside its existing team. For manufacturers sourcing whole-food ingredients, botanical extracts, or custom formulation support from RFI, the news signals expanded capital for international growth rather than a change in ownership control or day-to-day operations.

"For 37 years, we have built RFI Ingredients on a simple conviction: quality starts in the field," noted Wuagneux. "Nutraceutical, functional food, and beverage brands increasingly want a global partner with the scale, science, and supply integrity. In Astanor, we found a partner who understands our industry deeply, shares our from field to formula philosophy, and brings the experience to help us grow in Europe and APAC as well as develop science and clinically-backed ingredients."

What Is the Structure of the Astanor Investment?

The deal represents the second investment under Astanor's Astanor Growth strategy, which the firm describes as targeting profitable, category-leading companies across the agrifood value chain.¹

The transaction was completed alongside 2 additional French investors, Aurae, a Paris-based impact investment fund focused on regenerative agriculture and natural ingredient supply chains, and La Maison Partners, a firm that brins patient capital and a cross-border industrial network. RFI stated that any future acquisitions it makes using this capital will be integrated under the RFI brand.

Neither the release nor the companies disclosed the size of the investment or RFI's resulting valuation.

How Does This Fit Into the Broader Dietary Supplement and Functional Food Market?

RFI's announcement describes the company as primarily serving a combined $130 billion US dietary supplement and functional food and beverage market. Market research firms typically size these as separate categories; Grand View Research estimated the US dietary supplements market alone at $68.74 billion dollars in 2025, with growth projected to reach approximately $131 billion by 2033.²

What Should Manufacturers Take From the Astanor Partnership?

Eric Archambeau, founder and senior managing partner at Astanor, framed the deal as evidence of the firm's approach to private equity investment in the sector. "The partnership is the perfect example of what Astanor Growth additivity is in the low mid-market private equity: building trust with founders and management years before any transaction happens and showing that capital flexibility and industry expertise unlock bilateral win-win situations," he said.

Benoit Boisseuil, partner at Astanor, added that the firm has "been impressed by RFI's growth trajectory outpacing market rate consistently over the cycles, while being self-financed to date."¹ Those characterizations reflect the investors' own assessment of RFI's performance rather than independently disclosed financial results, since the release does not include revenue figures, growth rates, or other performance data to support the comparison.

What Are the Open Questions Following This Announcement?

The announcement does not specify a timeline for the planned European and Asia-Pacific expansion, but manufacturers with existing supply relationships tied to RFI may want to follow up directly on how the investment could affect lead times, pricing, or product availability as the company pursues international growth.

References

1. RFI Ingredients. RFI Ingredients accelerates global growth through strategic partnership with Astanor. July 29, 2026. Accessed July 29, 2026. https://rfiingredients.com/rfi-ingredients-accelerates-global-growth-through-strategic-partnership-with-astanor/

2. Grand View Research. US dietary supplements market (2026-2033). December 2025. Accessed July 29, 2026. https://www.grandviewresearch.com/industry-analysis/us-dietary-s